NSI-189 and Brain Health: What Labs to Watch and Why

Medical disclaimer: The information in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Lab results and reference ranges vary by individual, lab, age, sex, and health history. Always consult a qualified healthcare provider before making any decisions about your health, medications, supplements, or lab testing. LabHealthCharts is a data visualization tool — it organizes and displays your lab data, it does not interpret your results or provide medical guidance.

A synthetic nootropic that targets the hippocampus

NSI-189 is a synthetic small-molecule compound originally synthesized by Neuralstem, Inc. with the stated aim of stimulating neurogenesis — the growth of new neurons — in the hippocampus, the brain region most associated with learning, memory consolidation, and mood regulation. It does not belong to a natural peptide family, but it circulates in the same research and self-experimentation communities that follow peptide science, and it appears on LabHealthCharts under the cognitive and neuro peptide category because the audience and the monitoring questions overlap significantly.

Unlike most compounds in this space, NSI-189 has actually been tested in registered human clinical trials. That makes it unusual — and means the conversation can be grounded in published data rather than animal models alone. What those trials found is more nuanced than the community hype suggests, which is precisely why understanding the biomarker picture matters.

What the clinical trial data actually shows

The most cited human study is a Phase 1b/2a randomized controlled trial published in Molecular Psychiatry in 2016, led by Fava and colleagues. Forty-eight adults with major depressive disorder received NSI-189 phosphate at 40 mg, 80 mg, or placebo over eight weeks. The compound showed signals on some subjective cognitive measures and the Montgomery-Åsberg Depression Rating Scale (MADRS), but the primary endpoint — clinician-rated depression score — did not reach statistical significance versus placebo. The authors described the results as exploratory.

A follow-on Phase 2 trial reported in Acta Psychiatrica Scandinavica (2019) enrolled a larger group of MDD patients and again found no statistically significant separation from placebo on its primary cognitive endpoints, though some secondary measures trended in a positive direction. The trial was also not powered as a definitive efficacy study. In plain terms: the human evidence suggests biological plausibility and a reasonable safety signal, but NSI-189 has not been shown to definitively improve mood or cognition in registered trials to date.

Preclinical animal work, including research summarized in Behavioral Brain Research, has demonstrated hippocampal volume increases and improved spatial learning in rodent models. This is where the neurogenesis hypothesis originates. Extrapolating rodent data to humans is always uncertain — the hippocampus is proportionally different and human mood regulation involves more distributed circuitry — but the animal findings are what drew clinical researchers to test it in the first place.

Why self-experimenters track labs alongside NSI-189

Because NSI-189 is not a prescription drug in the US and sits outside standard clinical monitoring frameworks, people who use it are, by definition, doing so without a formal protocol. That makes self-tracked labs one of the few objective data sources available to them. The relevant biomarker categories fall into roughly three areas: baseline metabolic health, liver and kidney safety markers, and neuroendocrine markers that may connect to mood and cognition.

This is the same logic that applies across the cognitive and neuro peptide space — compounds like Selank also prompt their user base to track metabolic and hormonal baselines, not because the compounds are known to disrupt those systems dramatically, but because establishing a personal baseline before and after is the only rational way to notice if something unexpected changes.

Metabolic baseline: glucose, insulin, and HbA1c

Brain function is tightly coupled to glucose metabolism. The hippocampus — the specific region NSI-189 targets in its neurogenesis hypothesis — is particularly sensitive to insulin signaling and glucose availability. Research published in Neurobiology of Aging has documented that insulin resistance correlates with reduced hippocampal volume and worse declarative memory, independent of age. So if someone's stated goal in exploring NSI-189 is cognitive support or mood, their baseline metabolic health is not a side issue — it may be the most important variable in the picture.

Fasting glucose (the amount of sugar in your blood after an overnight fast, reported in mg/dL), fasting insulin, and HbA1c (hemoglobin A1c — a three-month average of blood sugar levels, expressed as a percentage) together give a meaningful snapshot of metabolic regulation. Normal fasting glucose typically falls between 70 and 99 mg/dL; HbA1c below 5.7% is considered normal by major US guidelines, though some longevity-focused practitioners prefer values closer to 5.0–5.4%. Ranges vary by lab and method, so always check your report's reference interval.

In practice, a person who notices poor recall or low mood and is interested in compounds like NSI-189 should know whether insulin resistance is already present. Addressing metabolic dysfunction through diet, sleep, and exercise may produce more reliable cognitive benefit than any single compound — and the labs will tell you which story is actually playing out.

Liver and kidney safety: ALT, AST, creatinine, and eGFR

The Phase 1b/2a trial reported in Molecular Psychiatry included safety labs and found no clinically significant liver or kidney signal at the doses tested. That is reassuring context. Still, standard practice when adding any compound without long-term human safety data is to get a baseline comprehensive metabolic panel (CMP) — which includes alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the two main liver enzymes, as well as creatinine and estimated glomerular filtration rate (eGFR) for kidney function.

ALT is the more liver-specific of the two enzymes. Elevations above the reference range (roughly 7–56 U/L for most adults, though this varies by sex and lab) suggest hepatocellular stress. AST is less specific but rises in parallel with ALT during liver injury. eGFR estimates how efficiently the kidneys are filtering waste; a value above 60 mL/min/1.73m² is generally considered adequate, while declining eGFR over successive draws is the signal worth watching. A single result tells you a snapshot; a series of results over months tells you direction.

The neuroendocrine angle: cortisol, DHEA-S, and thyroid

People exploring NSI-189 for mood and cognition frequently have co-existing patterns worth checking: elevated chronic stress hormones, thyroid dysfunction, or low DHEA (dehydroepiandrosterone sulfate — an adrenal precursor hormone that declines with age and correlates with mood and memory in some research). These are not specific to NSI-189 as a compound; they are context variables that determine whether the person's neuroendocrine environment is even set up to support the hippocampal plasticity the compound hypothetically targets.

Thyroid function is particularly worth noting: subclinical hypothyroidism — where TSH (thyroid-stimulating hormone) is mildly elevated but free T4 remains in range — can produce cognitive slowing and low mood that closely mimics depression. The free T4 and free T3 relationship is a genuine diagnostic question before attributing cognitive symptoms to anything else. Checking TSH at minimum, and free T4 and free T3 if TSH is abnormal, rules out a correctable and common cause.

Morning serum cortisol (the stress hormone measured in the blood, typically collected between 7 and 9 a.m.) and DHEA-S round out the adrenal picture. Chronically elevated cortisol is directly neurotoxic to the hippocampus in animal models and associated with memory impairment in humans. DHEA-S has a broad reference range that changes substantially with age — values that appear normal for a 60-year-old would be low for a 35-year-old — so comparing your number against an age-stratified range matters more than a single cutoff.

Inflammation markers: hsCRP and homocysteine

Neuroinflammation is a proposed mechanism in both depression and cognitive decline, and systemic inflammatory markers give indirect but accessible signals about what is happening in the brain's environment. High-sensitivity C-reactive protein (hsCRP — a protein the liver produces in response to inflammation, measured in mg/L) is a widely available marker. Values below 1.0 mg/L are generally considered low cardiovascular and inflammatory risk; above 3.0 mg/L suggests elevated systemic inflammation. A 2020 meta-analysis in Brain, Behavior, and Immunity confirmed that elevated CRP is significantly associated with depression risk across large population samples.

Homocysteine — an amino acid byproduct of methionine metabolism that accumulates when B-vitamin status (B6, B12, folate) is inadequate — is a lesser-known but important brain health marker. Elevated homocysteine (above approximately 15 micromol/L) is associated with accelerated hippocampal atrophy and increased dementia risk in longitudinal cohort research, including a notable study from the Oxford Project to Investigate Memory and Ageing. If someone is interested in compounds targeting hippocampal neurogenesis, knowing whether their homocysteine is already elevated — a readily correctable problem with B-vitamin supplementation under clinical guidance — is arguably higher yield than adding NSI-189.

A practical lab panel summary for the NSI-189 user base

What matters more than the compound: the whole-person metabolic picture

The biomarker list above is not unique to NSI-189. It is essentially the metabolic and neuroendocrine panel that any person concerned about long-term brain health should understand — regardless of whether they are exploring any compound at all. The reason it matters especially here is that the hypothesized mechanism of NSI-189 (hippocampal neurogenesis) requires a biological environment that is not hostile to new neuron growth. Chronic high cortisol, insulin resistance, elevated homocysteine, and systemic inflammation each suppress the conditions neurogenesis needs. Tracking these markers gives you a real picture of that environment.

Diet and lifestyle interventions have well-documented effects on several of these markers. Resistance training improves insulin sensitivity and is among the more robustly replicated lifestyle interventions for HbA1c reduction, as supported by a systematic review and meta-analysis in Diabetologia. Mediterranean-style eating patterns reduce hsCRP across multiple RCTs, including analyses from the PREDIMED trial published in Annals of Internal Medicine. Adequate B12 and folate intake brings homocysteine down in most people with mild elevation. Sleep duration affects morning cortisol and insulin sensitivity both. These are not alternatives to medical care — they are the environmental context your labs measure.

For anyone running labs alongside a nootropic like NSI-189, the most valuable use of the results is not to confirm that the compound is "working" in any single draw. It is to watch whether the underlying metabolic variables are moving in a healthier direction across multiple tests over months. That trend is where signal lives. A single cortisol number or a single CRP value tells you today's snapshot; two or three draws over six to twelve months tell you whether your environment is improving.

Tracking these markers over time: why one draw is not enough

Nearly every marker in this panel has meaningful within-person variation from draw to draw. Fasting glucose can shift with sleep quality the night before, cortisol varies with the exact time of collection, and hsCRP spikes temporarily with any minor infection or physical stress. Getting labs once and filing the PDF gives you a reference point; running the same panel three months and six months later, and being able to see the numbers side by side, is when the picture becomes interpretable.

LabHealthCharts is built specifically for this. You upload lab PDFs from Quest, LabCorp, or most other common formats, and the AI-assisted extraction pulls your values into structured, longitudinal charts — so your HbA1c from February and your HbA1c from August appear on the same timeline, not in two separate folders. The same applies to hsCRP, cortisol, liver enzymes, lipids, and thyroid markers. You can see direction across months rather than comparing screenshots in different apps or papers in a stack.

If you track markers like homocysteine or hsCRP alongside metabolic and neuroendocrine markers, being able to view them all in one place — next to each other across time — changes what you can notice. A CRP that was 2.8 mg/L in January, 1.4 mg/L in April, and 0.9 mg/L in July tells a fundamentally different story than a single value labeled "within range." That narrative is exactly what longitudinal charts are for.

LabHealthCharts tracks 100+ biomarkers in one account, exports to Excel or PDF when you want to share with a clinician, and the first report is free. Unlimited reports run $99 per year. As always: the app organizes and visualizes your data — interpretation of what the trend means for your specific health situation stays with your healthcare provider. You can upload your labs and start charting these markers today.

Key Takeaways

NSI-189 is one of the few synthetic nootropics with published human clinical trial data, but the results are preliminary and do not yet support strong efficacy claims for depression or cognition. The biology is plausible; the human evidence is not conclusive.

The most useful labs to track alongside NSI-189 — or any compound in this cognitive/neuro category — are:

Metabolic markers (fasting glucose, HbA1c, fasting insulin) because hippocampal neurogenesis depends on insulin sensitivity. Liver and kidney function (ALT, AST, creatinine, eGFR) as a standard safety baseline. Neuroendocrine markers (morning cortisol, DHEA-S, TSH, free T4) because hormonal dysfunction can produce or worsen the symptoms someone might be hoping to address. Inflammation (hsCRP, homocysteine) because both are measurable, modifiable, and directly relevant to brain health.

Before attributing any cognitive or mood change to NSI-189, rule out thyroid dysfunction, insulin resistance, elevated homocysteine, and chronic elevated inflammation — all of which have clearer evidence-based interventions and show up directly on standard labs. Ask your doctor which of these panels makes sense to run at your next visit, and track the results over time to see whether the direction of change reflects the lifestyle and other changes you are making.